Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826) Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Hamilton, E.; Meisel, J.; Alemany, C.; Virginia, B.; Lin, N.; Wesolowski, R.; Mathauda-Sahota, G.; Makower, D.; Lawrence, J.; Faltaos, D.; Mitri, Z.; Sabanathan, D.; Clark, D.; Pluard, T.; Hui, R.; McCarthy, N.; Patel, M.

authors

Publication Date

  • October 1, 2022

webpage

published in

category

start page

  • S36

end page

  • S36

volume

  • 174